<< Live webcast of Vertex's presentations at UBS Global Life Sciences Conference | Reality television series helps to increase AQUAGOLD International's brand awareness >>

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

CEO of pSivida to discuss new technologies in retinal drug delivery at the San Diego Ophthalmic summit

Published on September 19, 2009 at 3:02 AM · No Comments

pSivida Corp, (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery company, today announced that Dr. Paul Ashton, CEO, will lead a discussion on New Technologies in Retinal Drug Delivery at the 5^th Annual Ophthalmic Drug Development and Delivery Summit to be held September 21-22, 2009 in San Diego.

Dr. Ashton will describe the anatomical and technical difficulties of drug delivery to the retina; the advantages and disadvantages of earlier approaches to overcome these obstacles; current attempts to achieve effective dosing to the retina and provide an outlook on future developments in retinal delivery.

More information on the Summit can be found at its website: http://www.pharmedassociates.com.

www.psivida.com

2a22f20e-48c3-4b54-84fe-6fea08387635|0|.0

Posted in: Pharmaceutical News

Tags: Cancer, Cytomegalovirus, Diabetic Macular Edema, Drug Delivery, Edema, Exercise, Pancreatic Cancer, Pfizer, Uveitis, VEGF

Related posts

Physical education with academics can improve test scoresWhen schools cut physical education programs so students can spend more time in the classroom, they ...
Genentech announces positive outcomes from Lucentis Phase III trial against DMEGenentech, a member of the Roche Group, today announced that two-year results from a pivotal Phase I...
First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trialCell Medica, a leading UK cellular therapeutics company that develops, manufactures and markets cell...
Beta-Pro expands operations to meet increasing demand in $2 billion hepatocyte marketBeta-Pro LLC, announced today that it has expanded its operations to accommodate increasing demands ...
Genmab announces Phase II ofatumumab study results in RRMS patientsGenmab A/S announced today encouraging results from an ofatumumab Phase II safety and pharmacokineti...
BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccineBioVex Inc, a private biotechnology company developing new generation biologics for the treatment of...
King Pharmaceuticals receives exclusive rights to market and sell CYANOKITKing Pharmaceuticals, Inc. announced today that it has licensed from Merck Santé S.A.S., an affiliat...
Lux Biosciences announces results of its LX214 human safety study for dry eye syndromeLux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic ...
Microscopic needles effectively deliver drugs to the eyesA new technique that effectively delivers drugs to the eyes, using microscopic needles, could offer ...
Important to recognize difference between tiredness and fatigueInstead of dismissing grumblings about being tired or exhausted, people should take these complaints...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.